NASDAQ OMX

Block X Capital Corp. Announces Completion of Change of Business to Investment Issuer, Change of Name, Change of Management and Resumption of Trading

Dela

VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Block X Capital Corp. ("Block X" or the "Company") (CSE:BXXX) is pleased to announce that further to its press release on December 7, 2017, the Company has completed a change of business from a Mining Issuer to an Investment Issuer and has received approval from the Canadian Securities Exchange to resume trading.

In connection with the change of business, the Company has changed its name to "Block X Capital Corp.".  Trading of the Company's common shares will resume under the new name and under the new ticker symbol "BXXX" at market open on January 24, 2018.

The Company will seek investment opportunities in early-stage to mid-level blockchain and emerging technology companies, and will leverage its extensive network of operators and global thought leaders to provide investors with unparalleled access to investments that are not normally accessible to the average retail investor.

The Company is pleased to announce that it has appointed several notable individuals to form its core management team and board of directors.

  • Darius Eghdami: Chief Executive Officer

    A Chartered Accountant by trade, Darius Eghdami is a serial entrepreneur, investor, and has successfully exited multiple companies. Darius has previously founded and led multiple businesses in digital, data analytics, and the consumer internet. Darius founded FansUnite in 2012, the first social sports book harnessing the power of Blockchain technology. Darius has extensive experience managing companies, raising capital, and developing overall vision and business frameworks. Additionally, Darius was recently named one of Canada's Next 150 Top Entrepreneurs by the TMX Group.
  • Rahim Rajwani: Chief Financial Officer

    Rahim Rajwani brings over 22 years of extensive public and private company experience to Block X Capital. Rahim began his career at Yorkton Securities, and then later moved on to Union Securities where he worked as Chief Compliance Officer and Vice President of Compliance with a primary focus on risk mitigation. Rahim served in successive roles of increasing responsibility at Salman Partners, moving from Chief Compliance Officer, to Vice President, to Managing Director. Rahim aims to bestow his deep expertise in the regulatory, compliance, risk mitigation, and M&A transaction fields in order to support Block X's process of identification, evaluation, and investment in the most promising blockchain and emerging technology companies.  
  • Michele Romanow: Director

    Michele Romanow is a serial entrepreneur who started three companies before her 30th birthday. A "Dragon" on CBC's hit show Dragons' Den, she is a co-founder of Buytopia.ca (acquired by EMERGE Commerce), SnapSaves (acquired by Groupon), and co-founder of Clearbanc, an online financial services platform. She is a Director for Whistler Blackcomb (acquired by Vail Resorts) (NYSE:MTN), Freshii (TSX:FRII), and SHAD Valley. Furthermore, Michele was included in the WXN's "100 Most Powerful Women in Canada", Forbes "Millennial on a Mission" list, and winner of the Toronto Board of Trade Award for entrepreneurs under 30.
  • Cale Moodie: Director

    Cale Moodie is currently Chief Executive Officer & Director of Neptune Dash Technologies (TSX-V:DASH), a builder and operator of Dash Masternodes and exclusive public investor in the Dash digital currency eco-system. He is also a co-founder of Brixton Metals (TSX-V:BBB). Previously, Cale was the Chief Financial Officer of Underworld Resources Inc. until its sale to Kinross Gold in June of 2010. Prior to becoming a successful public market executive of multiple companies, Cale worked for KPMG LLP's Vancouver Industrial Markets Group, with an emphasis on audits for mining and resource-based companies. Cale holds the CPA designation and is a graduate of the University of British Columbia.
  • Zyshan Kaba: Director

    A corporate and securities lawyer by background, Zyshan Kaba is a venture investor and advisor that focuses on financial technology, blockchain, and cryptoassets. With a deep interest in disruptive technology and emerging markets, he focuses on early stage technology companies and his experience covers a variety of areas, including legal counsel, business and regulatory strategy, product development, market research, token sale structuring and analysis, and raising venture capital. Zyshan is also a former executive of a venture backed financial technology company where he was Head of Business and Legal Affairs. Zyshan received his J.D. from the University of Toronto and is called to the bar in Ontario and the state of New York.

Darius Eghdami, CEO, states, "Today marks an incredible milestone for us as the Company has been hard at work surveying the emerging blockchain-enabled industry and is ready to now resume trading, invest its capital, and unlock value in the space. At Block X, we've assembled a world-class team of accomplished investors and pioneers in the emerging technology sector. We look forward to capitalizing on the skill and experience of this executive team we have put together to facilitate investment and create real shareholder value in some of the most promising and disruptive blockchain and emerging technology companies of today and tomorrow."

The Company also announces that Ian Harris, has resigned as director to pursue other opportunities.  The Company thanks Mr. Harris for his dedication to the Company and wishes him all the best in his future endeavors. 

On Behalf of the Company,

Darius Eghdami,  CEO

Tel: 604-628-5616

For Media Contact: 

Natalie Davidson 
natalie@brixmediaco.com 
778 955 8012




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Block X Capital Corp. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum